Remibrutinib

Major

Remibrutinib Colchicine Colcrys Explained Increased P-gp substrate exposure and an increased risk of P-gp substrates-related adverse reactions Details Remibrutinib Apixaban Eliquis Explained An increased risk of bleeding Details Remibrutinib Aspirin Acuprin® An increased risk of bleeding Details Remibrutinib Aspirin Rectal Aspirin An increased risk of bleeding Details Remibrutinib Betrixaban Bevyxxa® An increased risk of bleeding Details Remibrutinib Anagrelide Agrylin An increased risk of bleeding Details Remibrutinib Clopidogrel Plavix An increased risk of bleeding Details Remibrutinib Cyclosporine Injection Atopica Increased P-gp substrate exposure and an increased risk of P-gp substrates-related adverse reactions Details Remibrutinib Cyclosporine Ophthalmic Cequa Increased P-gp substrate exposure and an increased risk of P-gp substrates-related adverse reactions Details Remibrutinib Dabigatran Pradaxa® An increased risk of bleeding Details Remibrutinib Dabigatran Etexilate An increased risk of bleeding Details Remibrutinib Dalteparin Injection Fragmin An increased risk of bleeding Details Remibrutinib Dexamethasone Injection Decadron Reduced remibrutinib exposure and reduced efficacy of remibrutinib Details Remibrutinib Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Reduced remibrutinib exposure and reduced efficacy of remibrutinib Details Remibrutinib Digoxin Cardoxin® Increased P-gp substrate exposure and an increased risk of P-gp substrates-related adverse reactions Details Remibrutinib Dipyridamole Permole® An increased risk of bleeding Details Remibrutinib Edoxaban Savaysa An increased risk of bleeding Details Remibrutinib Encorafenib Braftovi Reduced remibrutinib exposure and reduced efficacy of remibrutinib Details Remibrutinib Enoxaparin Lovenox An increased risk of bleeding Details Remibrutinib Enoxaparin Injection Lovenox An increased risk of bleeding Details Remibrutinib Epoprostenol Flolan An increased risk of bleeding Details Remibrutinib Everolimus Afinitor Increased P-gp substrate exposure and an increased risk of P-gp substrates-related adverse reactions Details Remibrutinib Fondaparinux Arixtra An increased risk of bleeding Details Remibrutinib Fondaparinux Injection Arixtra An increased risk of bleeding Details Remibrutinib Heparin An increased risk of bleeding Details Remibrutinib Heparin Injection Lipo-Hepin® An increased risk of bleeding Details Remibrutinib Iloprost Aurlumyn An increased risk of bleeding Details Remibrutinib Ketoconazole Topical Extina® Foam Increased remibrutinib exposure and an increased risk of remibrutinib-related adverse reactions Details Remibrutinib Lefamulin Xenleta Increased remibrutinib exposure and an increased risk of remibrutinib-related adverse reactions Details Remibrutinib Lenacapavir Injection Sunlenca Increased remibrutinib exposure and an increased risk of remibrutinib-related adverse reactions Details Remibrutinib Lenacapavir Oral Sunlenca Increased remibrutinib exposure and an increased risk of remibrutinib-related adverse reactions Details Remibrutinib Letermovir Injection Prevymis Increased remibrutinib exposure and an increased risk of remibrutinib-related adverse reactions Details Remibrutinib Mitapivat Aqvesme Reduced remibrutinib exposure and reduced efficacy of remibrutinib Details Remibrutinib Nafcillin Injection Unipen® Injection Reduced remibrutinib exposure and reduced efficacy of remibrutinib Details

Moderate

Remibrutinib Levothyroxine Ermeza Increased risk of hypothyroidism Details